US M&A and equity raisings
3,392 deals since January 2025, with sources and adviser credits where available · as at 20 Nov 2026 · Venture rounds
Deals dated after 30 September 2026 are still being collected.
445 deals · US$333bndisclosed · Healthcare · Clear
Columns
| Date | Target | Vendor | Acquirer | Type | Status | Value US$m | Sector | Advisers |
|---|---|---|---|---|---|---|---|---|
| Feb 2026 | PrimeRx | – | RedSail Technologies | Acquisition | Completed | – | Healthcare Software | William Blair |
| Feb 2026 | Benefits All In | – | WestView Capital Partners | Stake | Completed | – | Business Services+2 | Latham & Watkins (buy-side) |
| Jan 2026 | Alma | – | Spring Health | Acquisition | Announced | – | Healthcare Software+1 | Gunderson Dettmer (sell-side)MTS Health Partners (sell-side)Cooley (buy-side)J.P. Morgan (buy-side) |
| Jan 2026 | ArcRev | – | Symmetry Laser | Acquisition | Completed | – | Contract Manufacturing+1 | Covington & Burling |
| Jan 2026 | Repare Therapeutics | – | XenoTherapeutics | Acquisition | Completed | – | Biotech+1 | Cooley (sell-side)Stikeman Elliott (sell-side) |
| Jan 2026 | SubjectWell | – | – | Merger | Announced | – | Clinical Trial Services | Stout (sell-side)Fairmount Partners (buy-side) |
| Jan 2026 | Resolution Medical | Arcline Investment Management | Resonetics | Acquisition | Announced | – | Medtech+1 | Piper Sandler (sell-side)Bass, Berry & Sims (sell-side)Fredrikson & Byron (sell-side)Nelson Mullins Riley & Scarborough (buy-side) |
| Jan 2026 | HomeWell Care Services | – | Main Post Partners | Acquisition | Announced | – | Healthcare Services+2 | Boxwood Partners (sell-side) |
| Jan 2026 | Ganymede | – | Apprentice.io | Acquisition | Announced | – | Software+1 | Cooley (buy-side) |
| Jan 2026 | BioTissue non-ocular Surgical and Wound Care business | BioTissue Holdings | BioStem Technologies | Asset sale | Completed | – | Medtech | Bass, Berry & Sims (sell-side) |
| Jan 2026 | Fillex | – | Morrison Value Add II | Stake | Announced | – | Healthcare Services+1 | Goodwin (buy-side) |
| Jan 2026 | StarLIMS | – | Turn/River Capital | Stake | Announced | – | Software+2 | |
| Jan 2026 | RAPT Therapeutics | – | GSK | Acquisition | Announced | 2,200.0 | Biotech+1 | J.P. Morgan (sell-side)Cooley (sell-side)Latham & Watkins (sell-side)Evercore (buy-side)A&O Shearman (buy-side) |
| Jan 2026 | Crestwood Medical Center assets and associated outpatient centers and practices | Community Health Systems subsidiary | Huntsville Hospital Health System | Asset sale | Completed | 459.0 | Healthcare Services | Leerink Partners (sell-side) |
| Jan 2026 | Penumbra | – | Boston Scientific | Acquisition | Announced | 14,500.0 | Medtech | Perella Weinberg Partners (sell-side)Davis Polk (sell-side)A&O Shearman (buy-side)Arnold & Porter (buy-side) |
| Jan 2026 | TerSera Infusion Specialty Therapies Business Unit (IST) | TerSera Therapeutics | ESTEVE | Asset sale | Pending | – | Pharma | Kirkland & Ellis (sell-side)Leerink Partners (sell-side)Perella Weinberg Partners (buy-side)Arnold & Porter (buy-side) |
| Jan 2026 | Keet Health | WebPT | Net Health Systems | Acquisition | Announced | – | Healthcare Software+1 | Latham & Watkins (buy-side) |
| Jan 2026 | Radius Health | Patient Square Capital | B-FLEXION Life Sciences | Acquisition | Announced | – | Pharma | Kirkland & Ellis (sell-side)Centerview Partners (sell-side) |
| Jan 2026 | InduPro Therapeutics | – | Eli Lilly and Company | Stake | Announced | – | Biotech+2 | Freshfields (buy-side) |
| Jan 2026 | Health Resources Optimization, Inc. (H/ROI) | – | EnableComp | Acquisition | Completed | – | Healthcare Services+1 | Greenberg Advisors (buy-side) |
| Jan 2026 | Integrity Orthopaedics | – | Smith+Nephew | Acquisition | Announced | 225.0 | Medtech | Sidley Austin (buy-side) |
| Jan 2026 | Verana Health | – | – | Merger | Announced | – | Healthcare Software+2 | BofA Securities (sell-side)Wilson Sonsini Goodrich & Rosati (buy-side) |
| Jan 2026 | Hayden Consulting Group | – | BGB Group | Acquisition | Completed | – | Pharma Services+2 | Morgan Lewis (sell-side)Clearsight Advisors (sell-side) |
| Jan 2026 | Ventyx Biosciences | – | Eli Lilly and Company | Acquisition | Announced | 1,200.0 | Biotech+2 | Jefferies (sell-side)Moelis & Company (sell-side)Wilson Sonsini Goodrich & Rosati (sell-side)BofA Securities (buy-side)Ropes & Gray (buy-side) |
| Jan 2026 | Aktana | – | PharmaForceIQ | Asset sale | Announced | – | Healthcare Software+2 | Canaccord Genuity |
| Jan 2026 | Emerald Textiles | Pacific Avenue Capital Partners | PureStar Linen Group | Acquisition | Completed | – | Business Services+2 | Lincoln International (sell-side)BakerHostetler (sell-side)Piper Sandler (sell-side)Davis Polk (buy-side)Jefferies (buy-side) |
| Jan 2026 | Dark Blue Therapeutics | – | Amgen | Acquisition | Completed | 840.0 | Biotech+2 | Goodwin (sell-side)BofA Securities (sell-side) |
| Jan 2026 | Mersana Therapeutics | – | Day One Biopharmaceuticals | Acquisition | Completed | – | Biotech+2 | TD Securities (sell-side)WilmerHale (sell-side)Gordon Dyal & Co. (buy-side)Fenwick & West (buy-side) |
| Jan 2026 | Nivagen Pharmaceuticals | – | PAI Pharma | Acquisition | Announced | – | Pharmaceutical Manufacturing+1 | Bourne Partners (buy-side)Kirkland & Ellis (buy-side)KPMG (buy-side) |
| Jan 2026 | PTC Therapeutics' remaining royalty on Roche's Evrysdi | PTC Therapeutics | Royalty Pharma | Asset sale | Announced | 240.0 | Specialty finance and leasing+2 | Goodwin (buy-side) |
| Jan 2026 | Evidinno Outcomes Research | – | United BioSource | Acquisition | Completed | – | Pharma Services+2 | Fairmount Partners (sell-side) |
| Jan 2026 | Conformal Medical | – | W. L. Gore & Associates | Acquisition | Announced | – | Medtech+1 | Davis Polk (buy-side) |
| Jan 2026 | Tegria Services Group | Providence St. Joseph Health | Altaris | Acquisition | Completed | – | Healthcare Services+1 | Clearsight Advisors (sell-side) |
| Jan 2026 | BioRender | – | Dimension Capital | Stake | Announced | 900.0 | Software+2 | Sidley Austin (sell-side) |
| Jan 2026 | ROI Healthcare Solutions | – | Acuvance | Acquisition | Announced | – | IT Services+2 | Kirkland & Ellis (buy-side) |
| Jan 2026 | Valencia Technologies | – | Boston Scientific | Acquisition | Announced | – | Medtech | Latham & Watkins (buy-side) |
| Jan 2026 | HBox | – | Charlesbank Capital Partners | Stake | Announced | – | Healthcare Software+1 | Brown Gibbons Lang & Company (buy-side) |
| Jan 2026 | Centauri Health Solutions | – | Elevate Patient Financial Services | Acquisition | Completed | – | Healthcare Software+1 | William Blair |
| Jan 2026 | Medical Manufacturing Technologies (MMT) | – | Perimeter Solutions | Acquisition | Completed | 685.0 | Medtech+1 | William BlairBaird (buy-side) |
| Jan 2026 | Wonderbelly | – | Procter & Gamble | Acquisition | Completed | – | Consumer Health+1 | Perella Weinberg Partners (sell-side) |
| Jan 2026 | Lantheus SPECT business | Lantheus | SHINE Technologies | Asset sale | Announced | – | Pharma+2 | Solomon Partners (sell-side) |
| Jan 2026 | Orchid Orthopedic Solutions | – | – | Merger | Announced | – | Medtech+2 | Kirkland & Ellis |
| Jan 2026 | Burlington Medical | Peninsula Capital Partners | TIDI Products | Acquisition | Completed | – | Medtech | Baird (sell-side) |
| 2026 | Heritage Imaging | – | Align Capital Partners | Acquisition | Completed | – | Healthcare Services | Cascadia Capital |
| 2026 | TFP Fertility Group | – | Amulet | Stake | Announced | – | Healthcare Services | Lincoln International (buy-side) |
| 2026 | Egetis | – | ANI Pharmaceuticals | Acquisition | Announced | 560.0 | Pharma+1 | Centerview Partners (sell-side) |
| 2026 | Surgery Partners | – | Bon Secours Mercy Health | Acquisition | Announced | 5,700.0 | Healthcare Services | Centerview Partners (sell-side) |
| 2026 | Option Care Health | – | CD&R | Acquisition | Announced | 5,800.0 | Healthcare Services | Centerview Partners (sell-side) |
| 2026 | Calytrix Bio | – | Eli Lilly | Acquisition | Announced | 1,500.0 | Biotech | Centerview Partners (sell-side) |
| 2026 | AttaiBeckley | – | Eli Lilly and Company | Acquisition | Announced | 3,800.0 | Biotech+2 | Moelis & Company (sell-side) |
Deals come from SEC filings (merger proxies, tender offers, 8-K announcements and IPO prospectuses), the deal pages and transaction lists of law firms and banks, companies' press releases and the press. How the data is built